A5066781170- Cystic Fibrosis Research Advances
- Sinusitis and nasal conditions
- Mycobacterium research and diagnosis
- Inhalation and Respiratory Drug Delivery
- Lymphoma Diagnosis and Treatment
- Pediatric health and respiratory diseases
- Asthma and respiratory diseases
- COVID-19 and healthcare impacts
- HIV/AIDS drug development and treatment
- Drug-Induced Adverse Reactions
- Medical Imaging and Pathology Studies
- Global Health Workforce Issues
- Food Security and Health in Diverse Populations
- Pneumocystis jirovecii pneumonia detection and treatment
- Diversity and Career in Medicine
- Neonatal Respiratory Health Research
- Child Nutrition and Water Access
- Bacterial biofilms and quorum sensing
- Lung Cancer Research Studies
- Antibiotic Resistance in Bacteria
University of Pittsburgh
2022-2024
Johns Hopkins University
2020-2024
Children's Hospital of Pittsburgh
2024
University of Pittsburgh Medical Center
2024
Johns Hopkins Medicine
2024
Stanford University
2023
Abstract Background While the widespread initiation of elexacaftor/tezacaftor/ivacaftor (ETI) has led to dramatic clinical improvements among persons with cystic fibrosis (pwCF), little is known about how ETI affects respiratory mucosal inflammatory and physiochemical environment, or these changes relate lung function. Methods We performed a prospective, longitudinal study adults CF chronic rhinosinusitis (CF‐CRS) followed at our center ( n = 18). Endoscopic upper tract (paranasal sinus)...
Today, more than 90% of people with cystic fibrosis (pwCF) are eligible for the highly effective transmembrane conductance regulator (CFTR) modulator therapy called elexacaftor/tezacaftor/ivacaftor (ETI) and its use is widespread. Given drastic respiratory symptom improvement experienced by many post-ETI, clinical studies already underway to reduce number therapies, including antibiotic regimens, that pwCF historically relied on combat lung disease progression. Early suggest bacterial burden...
Chronic rhinosinusitis (CRS) is a common, yet underreported and understudied manifestation of upper respiratory disease in people with cystic fibrosis (CF). Recently developed standard care guidelines for the management CF CRS suggest treatment airway may ameliorate lower disease. We sought to determine whether changes sinus microbial community diversity specific taxa known cause lung are associated increased inflammation. performed 16S rRNA gene sequencing, supplemented cytokine analyses,...
Food insecurity (FI) rates among people with cystic fibrosis (CF) are significantly higher than in the general US population. This study explored experiences and perceptions of adults parents children CF surrounding FI. We recruited ages 0–18 years 18 older from a large, accredited U.S. care center Cystic Fibrosis Foundation Community Voice to participate qualitative using semi-structured telephone interviews explore preferences related food insecurity. Two coders independently reviewed each...
Abstract Background and Objectives The SARS‐CoV‐2 pandemic shifted medical training programs to utilize virtual interviews (VIs) starting with the 2020 interview cycle. Fellowship continue in format. It is unknown how this shift has affected equity for applicants as compared in‐person interviews. Equity study includes consideration of opportunity an applicant accept, access, conduct a VI. This assessed pediatric pulmonary fellows' perception associated VIs preferences future cycles. Methods...
Abstract Background Chronic rhinosinusitis (CRS) is a common, yet underreported and understudied manifestation of upper respiratory disease in people with cystic fibrosis (CF). There are currently no standard care guidelines for the management CF CRS, but treatment airway may ameliorate lower disease. We sought to inform future by determining whether changes sinus microbial community diversity specific taxa known cause lung associated increased inflammation. Methods performed 16S rRNA gene...